JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - PROKIDNEY CORP
Financial Performance:
- No specific financial results (revenue, earnings, cash flow, debt) provided as the company is in the clinical development phase with no commercial revenue.
- Manufacturing costs and pricing strategy discussed: Dialysis costs $100,000+ annually in the US; pricing expected to align with cell therapy comps ($400k-$500k) to capture value by preventing dialysis.
- Capital requirements for scaling from current 350-500 annual doses to potential 3,000 doses will require future investment (dilutive, partnerships, or debt).
Guidance and Future Outlook:
- Enrollment for the 320-patient accelerated approval cohort completed in Q1 2027; total enrollment expected to exceed 500 patients.
- Primary readout for accelerated approval (based on eGFR surrogate endpoint) anticipated in Q2 2027.
- BLA submission targeted for Q1 2028 to allow time for manufacturing process validation and facility inspections.
- Confirmatory trial data (composite endpoint) expected in the second half of 2029.
- Market opportunity focuses on the ~1 million US patients with Stage 3b/4 CKD and diabetes who progress despite standard of care.
Business Segments and Product Lines:
- Product: RuparinCell (Rilparencel), an autologous cell therapy designed to delay dialysis/transplant in diabetic CKD patients.
- Mechanism: Two-injection regimen (one per kidney) utilizing a paracrine mechanism to attenuate oxidative damage and inflammation; cryopreserved formulation used in Phase III.
- Manufacturing: Company-owned facility currently producing Phase III product; capacity of 350 doses/year at launch, expanding to 500 doses/year within one year via an adjacent building, with potential for 3,000 doses in a few years via additional expansion or CDMO partnerships.
Market and Competitive Landscape:
- Competes in a landscape of four established "pillars" of care: ACE inhibitors/ARBs, SGLT2 inhibitors, non-steroidal MRAs, and GLP-1s.
- ProKidney positions RuparinCell for the "residual risk" patient population that continues to progress on standard of care.
- Global dialysis costs vary, but the US market is a primary focus; significant economic value proposition exists by avoiding dialysis costs and preserving patient workforce participation.
- Market size for the specific target population is a sub-fraction of the 1 million advanced CKD patients, yet deemed substantial for a one-to-two-time therapy.
Risks and Challenges:
- Enrollment/Manufacturing Delays: Recent surge in recruitment pushed Phase III enrollment completion to Q1 2027 and BLA filing to Q1 2028 to ensure patient eligibility and facility inspection readiness.
- Safety Concerns: Primary safety focus is on complications from kidney biopsy and injections (bleeding, infection, local hematoma); low dropout rate (<3%) observed between first and second injection.
- Regulatory Path: Reliance on accelerated approval via surrogate endpoint (eGFR slope) requires subsequent confirmatory trial data on composite clinical events.
- Commercial Scale: Current manufacturing capacity (350-500 doses) is insufficient to meet the potential market demand, necessitating significant capital expenditure or partnerships.
Management Commentary and Tone:
- Tone is confident yet conservative regarding clinical assumptions; management emphasizes conservative power calculations (1.5 mL/min difference vs. Phase II's 4.5 mL/min) to ensure statistical significance.
- Leadership expressed strong conviction in the "paracrine" mechanism and the systemic therapeutic effect despite local injection.
- Clear acknowledgment of the logistical challenges in scaling manufacturing and the timeline implications of high enrollment volumes.
- Focus remains strictly on the advanced diabetic CKD market; no immediate plans to expand upstream or into other indications.
Analyst Questions and Answers:
- Pricing: CFO noted pricing will likely sit between $400k-$500k, justified by the $100k+ annual cost of dialysis and recent cell therapy comps (e.g., Iqems).
- Study Design: Confirmed Phase III is powered to detect a 1.5 mL/min eGFR slope difference; sham group decline assumed at 3.0 mL/min based on meta-analysis, though real-world untreated decline may be higher (5-6 mL/min).
- Data Readout: Top-line eGFR and safety data expected Q2 2027; full dataset and confirmatory composite event analysis to be presented at ASN Kidney Week in late 2027.
- Manufacturing: Current facility produces cryopreserved product; secondary facility expansion (500 doses) and potential CDMO usage planned to reach 3,000 doses annually.
- RMAT Status: Confirmation that RMAT designation was granted based on Phase II 002 data showing significant impact in advanced illness, without a sham group in the original designation request.
Other Key Points:
- Patient Compliance: Unlike daily chronic medications (8-12 drugs average for this population), RuparinCell requires only two injections with no further medication adherence required.
- Safety Profile: No significant off-target effects observed; bleeding events are consistent with standard kidney biopsy risks; no severe adverse events attributed specifically to the cell therapy in blinded reviews.
- Hazard Ratio: Conservative assumption for confirmatory trial is a hazard ratio of 0.6 for the composite clinical endpoint.
- Target Population: Enrollment strategy specifically targets patients progressing despite standard of care, who represent the highest unmet medical need.
- Company
- PROKIDNEY CORP
- Keywords
- PROKIDNEY CORP